Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heat zaps thyroid cancer spots: new hope for neck nodes

NCT ID NCT03416686

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a minimally invasive procedure called radiofrequency to treat thyroid cancer that has spread to lymph nodes in the neck. It involves 14 adults who have already had surgery and radioactive iodine therapy. The goal is to see if the heat-based treatment can shrink or eliminate the cancerous nodes, reduce symptoms, and improve quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Apr 2019

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over age of 18 years * with differentiated thyroid cancer (papillary, follicular) histologically confirmed, and absence of anaplastic component * Previous treatment by total thyroidectomy and cervical lymph node dissection. * Previous treatment by at least 1 therapeutic radioactive iodine (minimum activity 740MBq) * Persistence on cervical ultrasound of at least 1 cervical metastatic lymph node, visible at ultrasound, small diameter between ≥10 mm and ≤30mm, volume maximum 20ml, spotted on a picture, and confirmed by cyto-punction * Signed informed consent Exclusion Criteria: * Location of LN metastasis with significant risk of local complication (nervous, vascular) according baseline ultrasound assessment * Patient carrier of a pacemaker or a defibrillator * Congenital or acquired hemostasis abnormality, anticoagulant therapy or double platelet antiaggregatory (aspirin and clopidogrel) * Hypersensitivity to local anesthetic * Poor general condition (performance status Eastern Cooperative Oncology Group (ECOG) \> 1) * Survival estimated less than 12 months * Patient who can't follow the instructions of RF therapy or who can't be followed during 2 years in order to meet the objectives of the study * Non affiliation to a social security * Pregnant or breast feeding women at the time of RF * Beta hormone chorionic gonadotrope (HCG) positive test (pregnancy) before RF therapy * Baseline cervical ultrasound, by expert operator trained to RF, not fulfilling feasibility criteria for RF realisation because of the location of LN metastasis or the way to reach it * Controlateral recurrent palsy on nasofibroscopy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differentiated thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Differentiated thyroid cancer

Contacts and locations

Locations

  • Hôpital Américain de Paris

    Neuilly-sur-Seine, France

  • Hôpital Laiboisière

    Paris, France

  • Hôpital Saint Louis

    Paris, Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.